Chemo-Free Triple Drug Combo Shows Durable Responses in Resistant Lung Cancer
A phase II trial finds amivantamab, lazertinib, and bevacizumab extend survival in EGFR-mutant NSCLC patients who failed standard targeted therapy.
Summary
A phase II clinical trial tested a chemotherapy-free three-drug combination — amivantamab, lazertinib, and bevacizumab — in patients with EGFR-mutant advanced non-small cell lung cancer who stopped responding to standard targeted therapy. The combination achieved a 39% best overall response rate and a median progression-free survival of nearly 11 months, among the longest reported in this resistant setting. Median overall survival reached 19.9 months. The triplet works by simultaneously blocking three cancer-driving pathways: EGFR, MET, and the blood vessel growth factor VEGF. While results are encouraging, the trial lacked a control group, making it hard to know how much of the benefit reflects the treatment versus patient selection. Larger randomized trials are needed to confirm these findings.
Detailed Summary
Lung cancer remains one of the most common and deadly cancers globally, and EGFR-mutant non-small cell lung cancer (NSCLC) is a major subtype affecting a large proportion of patients. Although targeted therapies called EGFR tyrosine kinase inhibitors (TKIs) have transformed treatment, virtually all patients eventually develop resistance and their disease progresses — leaving a critical unmet need for effective second-line options.
A phase II single-arm trial published in Lancet Respiratory Medicine now offers a promising chemotherapy-free answer. Researchers tested the combination of amivantamab, a bispecific antibody targeting both EGFR and MET receptors, alongside lazertinib, a third-generation EGFR TKI, and bevacizumab, an anti-angiogenic agent that blocks tumor blood vessel growth. Together, the triplet targets three distinct pathways tumors use to survive and spread.
The trial enrolled patients who had already progressed on a third-generation EGFR TKI. The 12-week objective response rate was 33%, and the best overall response rate reached 39%, meeting the study's primary endpoint. Notably, the median duration of response was 13.9 months and median progression-free survival was 10.9 months — figures the authors describe as among the longest ever reported in this resistant setting. Updated follow-up data showed median overall survival of 19.9 months.
Commentators noted the discordance between the modest response rate and the prolonged progression-free survival, raising questions about whether some patients enrolled were lower-risk to begin with. Without a randomized comparison arm, attributing all benefit to the drug combination is difficult. Selection bias cannot be ruled out.
For clinicians and patients, this represents an important signal: simultaneous blockade of EGFR, MET, and VEGF pathways may unlock durable disease control where single-pathway inhibition has failed. Randomized trials are essential to define which patients benefit most and to establish this regimen as a standard of care.
Key Findings
- Best overall response rate of 39% met the primary endpoint in patients resistant to third-generation EGFR TKIs.
- Median progression-free survival of 10.9 months is among the longest reported in this resistant NSCLC setting.
- Median overall survival reached 19.9 months with the chemotherapy-free amivantamab, lazertinib, and bevacizumab triplet.
- The triplet simultaneously targets EGFR, MET, and VEGF pathways, addressing multiple resistance mechanisms at once.
- Absence of a randomized control arm limits conclusions; patient selection bias may partly explain favorable outcomes.
Methodology
This is a news report summarizing a single-arm phase II clinical trial published in Lancet Respiratory Medicine, a high-credibility peer-reviewed journal. The evidence basis is prospective but uncontrolled, limiting causal inference. An accompanying editorial from an independent oncologist provides critical appraisal of the findings.
Study Limitations
The single-arm design without a randomized comparator makes it impossible to rule out enrollment of a lower-risk patient population as a driver of the favorable outcomes. The modest objective response rate relative to prolonged progression-free survival creates interpretive uncertainty. Readers should consult the primary Lancet Respiratory Medicine publication for full patient eligibility criteria, toxicity data, and statistical details.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: